Shikonin; C.I. 75535; Isoarneb

MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

Shikonin

CAS No. : 517-89-5

产品活性：Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC₅₀ of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway.

研究领域：Membrane Transporter/Ion Channel | Metabolic Enzyme/Protease | NF-κB | Anti-infection | Apoptosis

作用靶点：Chloride Channel | Pyruvate Kinase | NF-κB | HIV | TNF Receptor

In Vitro: Shikonin is an inhibitor of TMEM16A chloride channel with an IC₅₀ of 6.5 μM. Shikonin is also a specific inhibitor of PKM2 and can also inhibit tumor necrosis factor-α (TNF-α) and prevent activation of nuclear factor-κB (NF-κB) pathway. Shikonin at concentrations higher than 50 μM significantly inhibits ormal human keratinocytes (NHKs) viability, compare with that of control (P<0.05). Pretreatment with Shikonin for 2 h attenuates TNF-α-induced NF-κB p65 nuclear translocation. Treatments of Shikonin at 5 and 7.5 μM significantly inhibit the cell viability starting from 12 h and the inhibitory effects are presented in time-dependent patterns compare with the 0 h group in both cell lines. It is found that 5 μM Shikonin displays greater inhibition compare to 2.5 μM at the time points from 24 to 48 h. The invasiveness of U87 and U251 cells is significantly attenuated when treated with Shikonin at 2.5, 5, and 7.5 μM compare with the control group at 24 and 48 h (p<0.01).

In Vivo: Shikonin significantly inhibits the increase in IL-1β and TNF-α expression levels in the rat model of osteoarthritis, compare with those in the osteoarthritis group (P<0.01). The NF-κB protein expression level is significantly suppressed by Shikonin in the rat model of osteoarthritis, compare with that in the osteoarthritis group (P<0.01). The induction of the iNOS level is suppressed by treatment with Shikonin in the rat model of osteoarthritis, compare with that in the osteoarthritis group (P<0.01). The administration of Shikonin markedly weakens the up-regulation of COX-2 protein expression in the rat model of osteoarthritis, as compare with that in the osteoarthritis group (P<0.01). The elevation of caspase-3 activity is significantly reduced by Shikonin treatment in the rat model of osteoarthritis, compare with that in the osteoarthritis group (P<0.01). The downregulation of Akt phosphorylation is also significantly recovered by treatment with Shikonin in the rat model of osteoarthritis, compare with that in the osteoarthritis group (P<0.01).

相关产品：Apoptosis Compound Library | Anti-Infection Compound Library | Natural Product Library Plus | Antioxidants Compound Library | NF-κB Signaling Compound Library | Anti-Virus Compound Library | Differentiation Inducing Compound Library | Oxygen Sensing Compound Library | Natural Product Library | Anti-Cancer Compound Library | Metabolism/Protease Compound Library | Bioactive Compound Library Plus | Membrane Transporter/Ion Channel Compound Library | Doxorubicin hydrochloride | Chloroquine diphosphate | 5-Fluorouracil | BAY 11-7082 | Vorinostat | Panobinostat | TEPP-46 | Pyrrolidinedithiocarbamate ammonium | (-)-Epigallocatechin Gallate | Valproic acid | SN50 | Birinapant | Flavopiridol | Fasudil Hydrochloride | Triptolide | Dolutegravir | JSH-23 | Rocaglamide | Dihydroartemisinin | TAK-243 | Cenicriviroc | Tomatidine | BAY 11-7085 | Hydroxyurea | Probenecid | Sulfasalazine | Bictegravir | Maraviroc | NIK SMI1 | Rolipram

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。